rs12510549 — SLC2A9

SLC2A9 — The Uric Acid Thermostat

Uric acid¹¹ Uric acid
The end product of purine metabolism in humans; unlike most mammals, humans lack the enzyme uricase and must excrete uric acid via the kidneys is a Jekyll-and-Hyde molecule. At normal concentrations it acts as an antioxidant, but when levels climb — whether through overproduction from purine-rich foods, alcohol, or fructose, or through impaired renal excretion — urate crystals precipitate in joints, causing the excruciating inflammation of gout²² gout
A form of inflammatory arthritis caused by monosodium urate crystal deposition in joints, most commonly the big toe, ankle, and knee. About 90% of hyperuricemia cases are due to reduced kidney excretion rather than overproduction, and SLC2A9 is one of the most important genes governing that excretion rate.

The SLC2A9 gene³³ SLC2A9 gene
Solute Carrier Family 2 Member 9, also known as GLUT9, encodes a high-capacity urate transporter at the basolateral membrane of kidney proximal tubule cells encodes GLUT9, a facilitatory transporter that moves urate from renal proximal tubule cells back into the bloodstream — a reabsorption step that returns filtered urate to circulation rather than allowing it to be excreted in urine. Functional studies show GLUT9 transports urate at a Km of ~365 μM⁴⁴ Functional studies show GLUT9 transports urate at a Km of ~365 μM
Anzai et al. 2008 — confirmed GLUT9 saturable urate efflux kinetics, making it the highest-capacity urate reabsorber identified in the kidney. Common variants in the SLC2A9 locus are the largest genetic determinants of serum uric acid levels identified by GWAS, explaining 1–3% of population variance — larger effects than any other single locus.

The Mechanism

rs12510549 maps to chromosome 4 at position 10,274,843 (GRCh38), in the intergenic region upstream of SLC2A9. It is an unannotated regulatory variant — no direct gene annotation in current Ensembl releases — but it sits within a dense cluster of SLC2A9-linked GWAS signals and is in moderate linkage disequilibrium with functional coding and intronic variants in the gene. The variant tags a haplotype associated with altered SLC2A9 transcriptional regulation in kidney and liver, both tissues with high GLUT9 expression. The T allele (reference, major) is associated with higher SLC2A9 expression or activity, leading to greater urate reabsorption and higher serum uric acid. The C allele (alternate, minor) is associated with reduced reabsorption and lower uric acid levels. Each copy of the minor C allele decreases serum uric acid by approximately 0.30–0.35 mg/dL⁵⁵ Each copy of the minor C allele decreases serum uric acid by approximately 0.30–0.35 mg/dL
Brandstätter et al. 2008 — Diabetes Care cohort study confirming per-allele effect, consistent across European cohorts and representing a biologically meaningful shift given that the threshold for urate crystal formation is approximately 6.8 mg/dL.

The Evidence

Brandstätter et al. 2008⁶⁶ Brandstätter et al. 2008
Sex-specific association of SLC2A9 variants with uric acid modified by BMI. Diabetes Care. genotyped rs12510549 alongside three other SLC2A9 SNPs in 800 Bruneck Study participants and a Utah obesity cohort (n=1,869). Each C allele copy reduced uric acid by 0.30–0.35 mg/dL, with p-values reaching 10⁻¹⁴ to 10⁻²⁰ in fully adjusted analyses. Crucially, the effect was significantly stronger in women and was amplified by higher BMI — people with obesity showed larger per-allele uric acid differences than lean individuals.

Stark et al. 2008⁷⁷ Stark et al. 2008
Association of common GLUT9 polymorphisms with gout but not coronary artery disease. PLoS One. tested all four SLC2A9 SNPs in 665 gout cases versus 665 matched controls. All four SNPs showed highly significant association with gout; for the lead SNP rs6855911, the allelic OR was 0.62 (95% CI 0.52–0.75; p = 3.2 × 10⁻⁷). rs12510549 showed similar directionality. Notably, the same variants showed no association with coronary artery disease, indicating the SLC2A9 locus acts specifically through uric acid rather than broader metabolic effects.

Lee et al. 2017⁸⁸ Lee et al. 2017
Meta-analysis of SLC2A9 polymorphisms and gout susceptibility. Z Rheumatol. pooled 11 comparative studies comprising 1,472 gout patients and 3,269 controls. For rs12510549 specifically, the C allele showed an OR of 0.641 (95% CI 0.54–0.76; p = 4.1 × 10⁻⁷) in overall analysis, with the effect driven primarily by Caucasian populations (OR 0.647, p = 1.2 × 10⁻⁶). The Asian subgroup showed a protective trend (OR 0.515) but was not statistically significant, possibly due to lower minor allele frequency in East Asians (~12%) and smaller sample sizes in Asian cohorts.

A sex-age interaction noted by Brandstätter et al. 2010⁹⁹ Brandstätter et al. 2010
Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis. — across 4,492 participants, the protective effect of the C allele on uric acid levels strengthens with increasing age in women, while attenuating with age in men. This is likely explained by estrogen's independent uricosuric effect: premenopausal women excrete more uric acid, masking genetic variation; after menopause, SLC2A9 genotype becomes more clinically relevant.

Practical Actions

The per-allele effect of 0.30–0.35 mg/dL is modest when viewed in isolation, but diet and lifestyle choices interact directly with the SLC2A9 transport system. Fructose and alcohol both acutely inhibit renal urate excretion — fructose via competition at urate transporters, alcohol via lactate accumulation that reduces tubular urate secretion. For TT homozygotes (about 65% of Europeans), who already have high urate reabsorption rates, these dietary inputs push uric acid levels disproportionately higher. Monitoring serum uric acid — especially after dietary changes or before adding purine-heavy protein sources — is the highest-value intervention for TT carriers.

Xanthine oxidase inhibitors (allopurinol, febuxostat) and uricosuric agents (probenecid, lesinurad) work regardless of SLC2A9 genotype but may be prescribed at different thresholds depending on baseline uric acid level, which is partly genetically determined.

Interactions

rs12510549 is in partial LD with several other SLC2A9 variants already in the platform: rs16890979 (Val282Ile, the main coding variant explaining the sex-specific urate effect), rs11942223 (intronic, independent second signal), and rs3733591 (Arg265His). Their combined effects on serum uric acid can be additive. The ABCG2 variant rs2231142 (Q141K) acts through a different mechanism — intestinal urate secretion rather than renal reabsorption — and compounds gout risk when co-occurring with high-risk SLC2A9 haplotypes. Users carrying both SLC2A9 T-risk haplotype and ABCG2 TT genotype face substantially elevated gout risk from both reduced intestinal excretion and increased renal reabsorption simultaneously.